« Return to News | Drug Sponsors

Renovo cuts jobs after Shire partnership ends

Thursday, March 3, 2011 02:44 PM

U.K.-based Renovo has halted spending and says it will lay off 100 workers in a broad restructuring that includes the possible sale of virtually all of its clinical assets, according to Fierce Biotech.

Shire ended its $825 million partnership with Renovo, handing back the rights to the anti-scarring drug Juvista, according to a statement from Renovo. The company is shelving its own work on the drug after concluding, "the efficacy of Juvista is insufficient to demonstrate significant benefit when tested in a broad population of scar revision patients."

Renovo CEO Mark Ferguson said, "We are extremely surprised and disappointed with the Juvista phase III trial result in scar revision surgery.  The board is seeking to maximize shareholder value from the remaining assets of Renovo." The company also said it would curtail recruitment in an ongoing trial of another drug, Adaprev, and will consider selling that program along with Juvista, Juvidex, Prevascar and all of its preclinical assets.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.